ArticleClinical and experimental immunology2008
Pharmacological targeting of C5a receptors during organ preservation improves kidney graft survival.
Article in Clinical and experimental immunology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 80 citations in OpenAlex.
- Improving kidney transplantation through the addition of pharmacological agents to hypothermic preservation solutions: a scoping review.Frontiers in pharmacology · 2025Review
- The Complement System in Kidney Transplantation.Cells · 2023Review
- Newly characterized bovine mammary stromal region with epithelial properties supports representative epithelial outgrowth development from transplanted stem cells.Cell and tissue research · 2022Article
- Complement-targeting therapeutics for ischemia-reperfusion injury in transplantation and the potential forFrontiers in immunology · 2022Review
- Renal diseases and the role of complement: Linking complement to immune effector pathways and therapeutics.Advances in immunology · 2021Review
- Targeted donor complement blockade after brain death prevents delayed graft function in a nonhuman primate model of kidney transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2020Article
- Guide to Immunopharmacology: a database to boost immunology education, research and therapy.Immunology · 2020Article
- Inflammaging and Complement System: A Link Between Acute Kidney Injury and Chronic Graft Damage.Frontiers in immunology · 2020Review
- Optimizing organs for transplantation; advancements in perfusion and preservation methods.Transplantation reviews (Orlando, Fla.) · 2020Review
- Complement Therapeutics in the Multi-Organ Donor: Do or Don't?Frontiers in immunology · 2019Review
- The multifaceted role of complement in kidney transplantation.Nature reviews. Nephrology · 2018Review
- A Gyrolab Assay for the Quantitation of Free Complement Protein C5a in Human Plasma.The AAPS journal · 2018Article
- Complement in Kidney Transplantation.Frontiers in medicine · 2017Review
- Complement involvement in kidney diseases: From physiopathology to therapeutical targeting.World journal of nephrology · 2015Review
- Mannan-binding lectin-associated serine protease 2 is critical for the development of renal ischemia reperfusion injury and mediates tissue injury in the absence of complement C4.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2014Article
- Dissecting the complement pathway in hepatic injury and regeneration with a novel protective strategy.The Journal of experimental medicine · 2014Article
- The immunomodulatory role of carbon monoxide during transplantation.Medical gas research · 2013Article
- Progress and Trends in Complement Therapeutics.Advances in experimental medicine and biology · 2013Article
- C3a and C5a promote renal ischemia-reperfusion injury.Journal of the American Society of Nephrology : JASN · 2012Article
- The role of complement in the early immune response to transplantation.Nature reviews. Immunology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cadaveric renal transplants suffer frequently from delayed graft function, which is associated with increased risk for long-term graft survival loss. One-third of kidney grafts that are stored in current organ preservation solutions experience delayed graft function, demonstrating the urgent need for improvement. Although ischaemic graft injury is complex in nature, complement activation is considered important to the process. Here we show that pharmacological targeting of the complement 5a receptor (C5aR) during cold ischaemia has a protective effect on early kidney graft survival, inflammation and apoptosis in a mouse model of syngeneic kidney transplantation. Graft survival of kidneys that were stored in University of Wisconsin solution in the presence of a C5aR antagonist increased from 29% to 57%. Increased graft survival was associated with less tubular damage and apoptosis, protection from sustained C5aR expression and decreased production of tumour necrosis factor-alpha and macrophage inflammatory protein-2. In a translational approach, we determined C5aR expression in paediatric living-related and cadaveric allografts. C5aR expression was significantly higher in all compartments of kidneys from cadaveric compared with kidneys from living-related donors. C5aR expression in cadaveric kidneys correlated positively with cold ischaemia time, renal dysfunction and the frequency of apoptotic tubular cells, suggesting a novel role for C5a in delayed graft function pathogenesis. Supplementing organ preservation solutions with C5aR inhibitors may improve early graft function following cadaveric kidney transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.